Searchable abstracts of presentations at key conferences in endocrinology

ea0065cc1 | FEATURED CLINICAL CASE POSTERS | SFEBES2019

Double somatic mutations of CTNNB1 and GNA11 in aldosterone producing adenomas (APAs) presenting in puberty, pregnancy or menopause

Zhou Junhua , Storr Helen , Cottrell Emily , Cabrera Claudia , Argentesi Giulia , Wu Xilin , Goodchild Emily , Azizan Elena , Brown Morris J

Objective: We reported 3 patients with primary aldosteronism who presented at times of high plasma LH, and had somatic CTNNB1 mutations causing ˜100-fold elevation of LHCGR in their APAs (Teo et al. NEJM 2015). Subsequently we identified 4 further patients, but the association with pregnancy was not found by others. Whole exome sequencing (WES) of an APA diagnosed at onset of puberty suggests an explanation.Method: WES of tumour and blood w...

ea0038p212 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Distinguishing different subtypes of aldosterone-producing adenoma by histological, immunohistochemical and radiological features; a basis for individualised treatment strategies in primary aldosteronism?

Powlson Andrew S , Teo Ada , Haris Lalarukh , Maniero Carmela , Marker Alison , Azizan Elena , Gurnell Mark , Brown Morris J

Background: Primary aldosteronism (PA) is now recognised to account for 5–10% of all cases of hypertension (and 20–25% of refractory hypertension). For patients with a demonstrable unilateral cause, adrenalectomy offers the potential for cure of PA, although resolution of hypertension occurs in only ~50% of patients. We have examined histological appearances and radiological features in patients with APAs undergoing adrenalectomy in an attempt to further our understa...

ea0034p365 | Steroids | SFEBES2014

11C-metomidate PET–CT in primary hyperaldosteronism: a valuable alternative to AVS

Powlson Andrew S , Koulouri Olympia , Challis Benjamin G , Cheow H K , Buscombe John , Koo Brendan , Brown Morris J , Gurnell Mark

Although adrenal vein sampling (AVS) remains the gold-standard for distinguishing unilateral and bilateral disease in primary hyperaldosteronism (PHA), it is technically demanding and not always feasible. Metomidate (MTO), a potent inhibitor of CYP11B1 and CYP11B2, can be C11H3-labelled as a PET tracer (11C-MTO), and we have previously shown it to be an alternative to AVS for localising unilateral aldosterone-producing adenomas (APAs) (Burton <...

ea0077oc4.1 | Adrenal and Cardiovascular | SFEBES2021

Development of [18F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of patients with Primary Hyperaldosteronism.

Sander Kerstin , Gendron Thibault , Cybulska Klaudia A. , Sirindil Faith , Zhou Jonhua , Kalber Tammy L. , Lythgoe Mark F. , Kurzawinski Tom R. , Brown Morris J. , Arstad Erik

Background: Inappropriately high aldosterone in patients with primary hyperaldosteronism (PHA) is due to increased aldosterone synthase (CYP11B2) activity. Selective in vivo imaging of overexpressed CYP11B2 in adrenals with positron emission tomography (PET) has not yet been achieved due to close homology of enzymes involved in aldosterone and cortisol (CYP11B1) synthesis.Aim: Synthesize a fluorine-18 labelled highly selective CYP11B2 inhibitor,...

ea0037oc1.4 | Adrenal 1 | ECE2015

11C-metomidate PET-CT in primary aldosteronism: five possible indications for a non-invasive alternative to adrenal vein sampling

Powlson Andrew S , Koulouri Olympia , Azizan Elena , Maniero Carmela , Taylor Kevin , Aigbirhio Franklin , Koo Brendan , Cheow Heok K , Buscombe John , Gurnell Mark , Brown Morris J

Background: Adrenal vein sampling (AVS) remains the gold-standard for distinguishing unilateral and bilateral disease in primary aldosteronism (PA). However, it is invasive, technically demanding, and may yield inconclusive or equivocal results. 11C-Metomidate PET-CT (11C-MTO-PET-CT) is a non-invasive alternative to AVS for localising unilateral aldosterone-producing adenomas (APAs).Methods/patients: We report a retrospective analys...

ea0086p7 | Adrenal and Cardiovascular | SFEBES2022

Adrenalectomy for unilateral primary aldosteronism improves quality of life: prospective analyses in the MATCH trial

Blackstone Brittany , Goodchild Emily , Tooze Oliver , Salsbury Jackie , Wu Xilin , Ronaldson Amy , Senanayake Russell , Bashari Waiel , Argentesi Giulia , O'Toole Samuel M. , Parvanta Laila , Sahdev Anju , Laycock Kate , Cruickshank Kennedy , Gurnell Mark , M. Drake William , Brown Morris J.

Background: After adrenalectomy (ADX) for primary aldosteronism (PA), approximately 30% of patients achieve clinical success (normalisation of home BP); many additional patients report feeling subjectively better. We used the non-randomised MATCH study1 to further assess quality of life (QoL) changes in participants.Objective: Assess QoL using the 36-item Short Form Health Survey (SF-36) after surgical treatment of unilateral PA and medical treatment of ...